Last reviewed · How we verify

NCT02785874

Statin With Palliative Therapy for HCC

Terminated NA Last updated 19 April 2017
What this trial tests

NA trial testing Statin in HCC in 4 participants. Terminated before completion.

Timeline
1 September 2016
Primary endpoint
1 October 2016
1 November 2016

Quick facts

Lead sponsorTaipei Medical University WanFang Hospital
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment4
Start date1 September 2016
Primary completion1 October 2016
Estimated completion1 November 2016
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei Medical University WanFang Hospital

Who can join

Adults 20 to 90, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Statin

Trials testing the same drug.

Other recruiting trials for HCC

Currently open trials in the same condition.

Other Taipei Medical University WanFang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02785874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing